Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more
Ovid Therapeutics Inc (OVID) - Total Liabilities
Latest total liabilities as of September 2025: $19.15 Million USD
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has total liabilities worth $19.15 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ovid Therapeutics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Ovid Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ovid Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Ovid Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alta Equipment Group Inc
NYSE:ALTG
|
USA | $1.43 Billion |
|
Progate Group Corporation
TWO:8227
|
Taiwan | NT$342.24 Million |
|
ECS ICT Bhd
KLSE:5162
|
Malaysia | RM525.53 Million |
|
Zhejiang Yingfeng Technology Co Ltd
SHG:605055
|
China | CN¥1.76 Billion |
|
CSB Bancorp Inc
PINK:CSBB
|
USA | $1.17 Billion |
|
Chen Full International Co Ltd
TWO:8383
|
Taiwan | NT$2.00 Billion |
|
Suven Life Sciences Limited
NSE:SUVEN
|
India | ₹561.36 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Ovid Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ovid Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ovid Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Ovid Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $23.94 Million | -57.42% |
| 2023-12-31 | $56.23 Million | +144.55% |
| 2022-12-31 | $22.99 Million | +55.38% |
| 2021-12-31 | $14.80 Million | -54.18% |
| 2020-12-31 | $32.29 Million | +198.46% |
| 2019-12-31 | $10.82 Million | +22.34% |
| 2018-12-31 | $8.84 Million | +46.89% |
| 2017-12-31 | $6.02 Million | +61.28% |
| 2016-12-31 | $3.73 Million | +61.68% |
| 2015-12-31 | $2.31 Million | +1825.09% |
| 2014-12-31 | $119.95K | -- |